Pfizer To Shut Down Its Manufacturing Units In Chennai & Aurangabad
US Pharma Giant Pfizer Inc has announced a closure of its two manufacturing units located in Chennai & Maharastra which it had acquired from Hospira under a pact made in 2015. Though Pfizer will retain the Vizag facility which came under the same deal and will be focusing on its expansion. More than 1700 employees working at these plants will be impacted by the decision.
After a thorough assessment of the Irungattukottai and Aurangabad facility, Pfizer expressed that because of a noteworthy fall in the demand of the products manufactured at these destinations, it’s infeasible for them to continue the operations there thus bringing about the shutdown of both the facilities in 2019.
Pfizer expressed that Currently 1000 individuals in Irungattukottai office and 700 individuals in Aurangabad site are employed and they completely understand the responsibility to keep them educated about the site leave process.
The Irungattukottai facility was creating beta-lactam anti-infection
agents while the Aurangabad office was delivering penicillin and penem API all through the period.The Chennai plant lately received a few notices from the US Food and Drug Administration, the most recent being in July 2018. This was on the grounds that it wasn’t following quality control norms and needs data identified with lab records.
The Irungattukottai and Aurangabad sites are absolutely export-oriented and don’t supply items for Pfizer’s India business tasks. There will be no impact by the decision to close down these facilities on other Indian manufacturing sites in Goa, Visakhapatnam (Vizag) and the joint venture site, Zydus Hospira Oncology Pvt Ltd (ZHOPL) Pfizer said.
Pfizer announced a development in their operations at the Vizag site to bring it up as a worldwide terminally cleaned manufacturing center of excellence. It will take into account the export markets, for example, the United States and in the long run, to Canada. India will keep on being a critical assembling area for Pfizer around the world, said the organization.
